Immuno Oncology Research Articles & Analysis
8 news found
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be ...
ByBayer AG
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence that had the mechanism of overcoming tolerance GI Innovation revealed ...
Most recently, Microbiotica entered a landmark collaboration in immuno-oncology with Cancer Research UK and Cambridge University Hospitals to develop microbiome co-therapeutics and biomarkers for cancer patients receiving checkpoint inhibitor therapy. In addition, the Company has existing programs in IBD and ...
Additionally, we are looking forward to further realizing the potential of the RTGel™ platform through strategic collaborations, such as our recent immuno-oncology research agreements with leading academic centers.” Business Highlights and Upcoming Milestones: Jelmyto (mitomycin) for pyelocalyceal solution: Achieved net product ...
Hans Schikan, non-Executive Chairman of Microbiotica, said: “Microbiome research is rapidly emerging as one of the most exciting areas of biomedicine and one that I believe presents great potential for a wide range of therapeutic fields. Microbiotica’s world-leading platform, ongoing collaborations and internal pipeline, especially in the ...
Thermo Fisher Scientific, the world leader in serving science, today announced it has completed the acquisition of Phitonex, Inc., a Durham, North Carolina-based company that has pioneered a spectral dye platform for high-resolution biology applications designed to accelerate research and development in cell therapy, immuno-oncology and ...
“We developed the tools and knowhow to help every immuno-oncology and cell therapy researcher excel at their job. This helps increase the speed in which drugs are developed and brought to market by elucidating their mechanisms of action and resistance.” The company was founded in December 2018 by ex-Harvard-MIT postdoc ...
ByImmunai
Thermo Fisher Scientific, the world leader in serving science, will present a series of abstracts that will highlight exciting advances in clinical research with applications in immuno-oncology, tumor biology and biomarker discovery during the American Association for Cancer Research (AACR) 2018 Annual Meeting (booth #1805) in ...